Modifying ART in the Presence of Hyperlipidemia: Using HIV-ASSIST
HIV is a risk-enhancing factor that favors initiation of statin therapy when it coexists with hyperlipidemia. Hear how Maunank Shah, MD, PhD, uses HIV-ASSIST to optimize management of both hyperlipidemia and HIV.
Decera Clinical Education Infectious Disease Podcast · Maunank Shah MD PhD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:
- Hyperlipidemia and cardiovascular disease risk among people living with HIV
- Recommendations for lipid screening for people living with HIV
- Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
- How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
- Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
- Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
- How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
- How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database
Maunank Shah, MD, PhD
Associate Professor
Infectious Diseases
Johns Hopkins University
Baltimore, Maryland
Link to full program: bit.ly/3pwaH2Y
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.